Volume | 97,946 |
|
|||||
News | - | ||||||
Day High | 3.1855 | Low High |
|||||
Day Low | 3.03 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NRX Pharmaceuticals Inc | NRXP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.13 | 3.03 | 3.1855 | 3.12 | 3.05 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
827 | 97,946 | $ 3.09 | $ 302,843 | - | 2.21 - 12.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:52:27 | 29 | $ 3.05 | USD |
NRX Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
261.83M | 83.92M | - | 0 | -30.16M | -0.36 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NRX Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRXP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.26 | 4.30 | 2.7201 | 3.12 | 288,885 | -1.21 | -28.40% |
1 Month | 5.293 | 6.00 | 2.7201 | 4.72 | 482,143 | -2.24 | -42.38% |
3 Months | 3.90 | 7.333 | 2.7201 | 5.11 | 1,506,088 | -0.85 | -21.79% |
6 Months | 2.789 | 7.333 | 2.603 | 4.70 | 1,145,377 | 0.261 | 9.36% |
1 Year | 5.70 | 12.00 | 2.21 | 4.20 | 1,026,935 | -2.65 | -46.49% |
3 Years | 230.10 | 262.40 | 2.21 | 69.35 | 1,613,479 | -227.05 | -98.67% |
5 Years | 230.10 | 262.40 | 2.21 | 69.35 | 1,613,479 | -227.05 | -98.67% |
NRX Pharmaceuticals Description
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. |